This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): INS117548
Description: INS117548 is a Rho kinase inhibitor designed to lower IOP in glaucoma patients by disrupting the actin cytoskeleton (cellular skeleton) of the trabecular meshwork, an ocular tissue responsible for most of the outflow of aqueous humor. The elevated IOP commonly associated with glaucoma is believed to arise from impairment in the function of the trabecular meshwork.
Deal Structure: The technology platform that led to the discovery of INS117548 is based on a license agreement with the Wisconsin Alumni Research Foundation for use in developing and commercializing new therapies to treat glaucoma.
In April 2011, Merck and Inspire Pharmaceuticals announced that they have entered into a definitive agreement under which Merck will acquire Inspire. In May 2011, Merck announced that it has completed its acquisition of Inspire Pharmaceuticals.
Additional information available to subscribers only: